TrialJournal of thrombosis and thrombolysis2018

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.

Paul A Gurbel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.